Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week

4. Spero Therapeutics, Inc. (NASDAQ:SPRO)

Spero Therapeutics soared by 259 percent week-on-week as investors cheered encouraging results of its potential treatment for urinary tract infection.

According to the company, its study for the oral drug tebipenem HBr, which it was developing in partnership with pharmaceutical giant GSK, showed that it was at least as good as an intravenous imipenem-cilastatin, a type of antibiotic, in hospitalized adult patients.

If approved, it could become the first oral carbapenem antibiotic for patients with cUTIs.

The news pushed the company to touch a new all-time high of $2.8 on Friday and propelled its price above the $1 level, having traded below the said price for 94 consecutive days.

Earlier this year, Spero Therapeutics, Inc. (NASDAQ:SPRO) received a letter from the Nasdaq notifying the company of failing to meet the minimum bid price requirement of $1.

As a Nasdaq-listed company, it is required to stay afloat the minimum requirement to stay listed, or face a potential delisting. Spero Therapeutics, Inc. (NASDAQ:SPRO) had until August 25 to regain compliance.